Anti-TNF Therapy Is Emerging as the Primary Treatment Modality in Pediatric Inflammatory Bowel Disease

被引：4
作者：
Niklinska-Schirtz, B. Joanna [1 ]
Kugathasan, Subra [1 ]
机构：
[1] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA
来源：
INFLAMMATORY BOWEL DISEASES | 2020年 / 26卷 / 01期
关键词：
CROHNS-DISEASE; CHILDREN; 6-MERCAPTOPURINE; METHOTREXATE; EXPERIENCE; TERM;
D O I：
10.1093/ibd/izz158
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
A population-based Canadian study found an increasing trend in utilization of anti-tumor necrosis factor agents in pediatric inflammatory bowel disease (IBD), also reporting that immunomodulator use is on the decline. This accompanying editorial discusses this emerging trend occurring in pediatric IBD world-wide. Data from the Risk Stratification and Identification of Immunogenetic and Microbial Markers of Rapid Disease Progression in Children with Crohn's Disease (RISK) study are presented and confirm the same trend among pediatric IBD in the United States.
引用
收藏
页码：139 / 140
页数：2
相关论文
共 50 条
  • [31] Targeting Interleukins for the Treatment of Inflammatory Bowel Disease-What Lies Beyond Anti-TNF Therapy?
    McLean, Mairi H.
    Neurath, Markus F.
    Durum, Scott K.
    INFLAMMATORY BOWEL DISEASES, 2014, 20 (02) : 389 - 397
  • [32] Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy
    Dahmus, Jessica
    Rosario, Michelle
    Clarke, Kofi
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2020, 13 : 339 - 350
  • [33] Effect of antinuclear antibodies on pharmacokinetics of anti-TNF therapy in patients with inflammatory bowel disease
    Theodoraki, Eirini
    Orfanoudaki, Eleni
    Foteinogiannopoulou, Kalliopi
    Andreou, Nikolaos-Panagiotis
    Gazouli, Maria
    Koutroubakis, Ioannis E.
    INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2022, 37 (03) : 639 - 646
  • [34] Endemic Fungal Infections in Inflammatory Bowel Disease Associated with Anti-TNF Antibody Therapy
    Ordonez, Miguel E.
    Farraye, Francis A.
    Di Palma, Jack A.
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (11) : 2490 - 2500
  • [35] Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease
    Peng, Jiang Chen
    Shen, Jun
    Ran, Zhi Hua
    JOURNAL OF DIGESTIVE DISEASES, 2014, 15 (11) : 585 - 590
  • [36] Effect of antinuclear antibodies on pharmacokinetics of anti-TNF therapy in patients with inflammatory bowel disease
    Eirini Theodoraki
    Eleni Orfanoudaki
    Kalliopi Foteinogiannopoulou
    Nikolaos-Panagiotis Andreou
    Maria Gazouli
    Ioannis E. Koutroubakis
    International Journal of Colorectal Disease, 2022, 37 : 639 - 646
  • [37] Anti-TNF Antibody Therapy for Inflammatory Bowel Disease During Pregnancy: A Clinical Review
    El Mourabet, Marwa
    El-Hachem, Sandra
    Harrison, Janet R.
    Binion, David G.
    CURRENT DRUG TARGETS, 2010, 11 (02) : 234 - 241
  • [38] Increased Discontinuation Rates of Anti-TNF Therapy in Elderly Inflammatory Bowel Disease Patients
    de Jong, M. E.
    Smits, L. J. T.
    van Ruijven, B.
    den Broeder, N.
    Russel, M. G. V. M.
    Romkens, T. E. H.
    West, R. L.
    Jansen, J. M.
    Hoentjen, F.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 (07) : 888 - 895
  • [39] Optimal Doses of Methotrexate Combined with Anti-TNF Therapy to Maintain Clinical Remission in Inflammatory Bowel Disease
    Colman, Ruben J.
    Rubin, David T.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 (04) : 312 - 317
  • [40] Strategic Use of Immunosuppressants and Anti-TNF in Inflammatory Bowel Disease
    Louis, Edouard
    DIGESTIVE DISEASES, 2013, 31 (02) : 207 - 212
12345